CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
This Document Has Been Replaced By: Prevention and Control of Meningococcal Disease : Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Superseded
This Document Has Been Replaced By: Prevention and Control of Meningococcal Disease : Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
-
March 12, 2010
-
Source: MMWR. Morbidity and mortality weekly report. 2010; 59(9):273.
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Corporate Authors:
-
Description:On February 19, 2010, the Food and Drug Administration (FDA) licensed a quadrivalent meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics). MenACWY-CRM is licensed as a single dose for use among persons aged 11-55 years. The Advisory Committee on Immunization Practices (ACIP) reviewed data from prelicensure clinical trials on the safety and immunogenicity of MenACWY-CRM. This report summarizes the approved indications for MenACWY-CRM and provides guidance from ACIP for its use. The following guidance for use of MenACWY-CRM is consistent with licensed indications and ACIP recommendations for meningococcal conjugate vaccines.
-
Subjects:
-
Source:
-
Series:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Pubmed ID:20224545
-
Place as Subject:
-
Pages in Document:1 pdf page
-
Volume:59
-
Issue:9
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-1.59 MB]